Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

Current Oncology

Volumn 19, Issue S1, 2012, Pages S13-S21

  Klotz, Laurence ^a   Toren, P ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Androgen deprivation therapy; prostate cancer; quality of life

Indexed keywords

EID: 84877054713     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1298     Document Type: Review

References (45)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941. J Urol 2002;168:9–12.
2. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(suppl 1):32–8.
3. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546–50. [Erratum in: Cancer 1987;59:43]
4. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782–90.
5. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275–82.
6. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58:139–46.
7. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007;99:1056–65.
8. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49–59.
9. Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer—biochemical results from a prospective phase ii study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007;109:858–67.
10. Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase ii study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 2008;6:46–52.
11. Bruchovsky N, Klotz L, Crook J, et al. Final results of the Canadian prospective phase ii trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006;107:389–95.
12. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1:163–71.
13. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105]. J Clin Oncol 2007;25:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47 &abstractID=33936; cited November 3, 2012]
14. Tunn UW, Canepa G, Hillger H, Fuchs W. Intermittent androgen deprivation in patients with psa-relapse after radical prostatectomy—final results of a European randomized prospective phase-iii clinical trial AUO study AP 06/95, EC 507 [abstract 600]. J Urol 2007;177:201. [Available online at: http://www.abstracts2view.com/aua_archive/view. php?nu=200791183; cited November 4, 1212]
15. Salonen AJ, Viitanen J, Lundstedt S, Ala–Opas M, Taari K, Tammela TL on behalf of the FinnProstate Group. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180:915–19.
16. Verhagen PCMS, Wissenburg LD, Wildhagen MF, et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (cpa) for metastatic prostate cancer [abstract 541]. Eur Urol Suppl 2008;7:206.
17. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269–77.
18. Mottet N, Goussard M, Wolff JM, Loulidi S. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial [abstract 171]. Am Soc Clin Oncol Genitourin Cancer Symp 2009;:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstract ID=20344; cited November 3, 2012]
19. Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising psa level after radiotherapy. N Engl J Med 2012;367:895–903.
20. Hussain M, Tangen CM, Higano CS, et al. Intermittent (iad) versus continuous androgen deprivation (cad) in hormone sensitive metastatic prostate cancer (hsm1pc) patients (pts): results of S9346 (int-0162), an international phase iii trial [abstract 4]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_ detail_view&confID=114&abstractID=92516; cited November 15, 2012]
21. Tunn U, Eckhart O, Kienle E, Hillger H. Intermittent androgen deprivation in patients with psa-relapse after radical prostatectomy—first results of a randomised prospective phase-iii clinical trial (AUO study AP06/95). Eur Urol Suppl 2003;2:24.
22. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ on behalf of the consort Group. Reporting of noninferiority and equivalence randomized trials: an extension of the consort statement. JAMA 2006;295:1152–60.
23. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase iii clinical trial using limited hormonal therapy. J Urol 2005;173:1567–71. [Erratum in: J Urol 2005;174:796]
24. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178:1290–5.
25. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105:648–51.
26. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010;70:745–54.
27. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2011;:[Epub ahead of print].
28. Spry NA, Galvão DA, Davies R, et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int 2009;104:806–12.
29. Malcolm JB, Derweesh IH, Kincade MC, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007;14:3551–9.
30. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933–41.
31. Malone S, Perry G, Eapen L, et al. Mature results of the Ottawa phase ii study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Biol Phys 2007;68:699–706.
32. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS on behalf of the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493–500.
33. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43:233–9.
34. Scholz MC, Lam RY, Strum SB, et al. Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer. Clin Genitourin Cancer 2011;9:89–94.
35. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial sakk 08/88. J Clin Oncol 2004;22:4109–18.
36. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (eortc) Trial 30891. J Clin Oncol 2006;24:1868–76.
37. Verhagen PC, Schröder FH, Collette L, Bangma CH. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010;58:261–9.
38. Messing EM, Manola J, Yao J, et al. on behalf of the Eastern Cooperative Oncology Group study est 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–9.
39. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002;59:73–8.
40. Sciarra A, Cattarino S, Gentilucci A, et al. Predictors for response to intermittent androgen deprivation (iad) in prostate cancer cases with biochemical progression after surgery. Urol Oncol 2011;:[Epub ahead of print].
41. Yu EY, Gulati R, Telesca D, et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010;28:2668–73.
42. Di Silverio F, Sciarra A, Gentile V. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology 2008;71:947–51.
43. Figg WD, Hussain MH, Gulley JL, et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 2009;181:1104–13.
44. Ward JE, Karrison T, Chatta G, et al. A randomized, phase ii study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase ii Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis 2012;15:87–92.
45. Scholz MC, Jennrich RI, Strum SB, Johnson HJ, Guess BW, Lam RY. Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 2006;175:1673–8.